The Velindre Cancer Centre provides closely integrated oncology and palliative care clinical services. In 1998 the centre began the integration of oncology and palliative care. This initially started on one ward where all patients were admitted under the oncologists and were automatically secondarily under the care of the palliative care team. This removed the requirement for individual patient referrals and established completely integrated working. This has been evaluated on three occasions since then and has been universally viewed by consultants in oncology and palliative medicine as improving patient care. The oncologist remains the primary consultant responsible and the palliative care consultant is the secondary care consultant while the patient is an inpatient.
The cancer centre provides the full range of non-surgical oncological treatments. There are linear accelerator machines for radiotherapy and dedicated in patient and out patient chemotherapy units as well as day treatment facilities. In addition there are facilities and expert care for in-patient end-of-life care and staff committed to providing adequate relief of suffering for dying patients. The centre incorporates programmatic support of family members including children, with a family room in which the patient's bed can be taken, allowing even the sickest young patients the privacy of being with their family in a children-orientated environment with a range of toys etc for every age. There is also specialist nursing support, integrated with the palliative care team, for families at such difficult times. The centre provides emergency care of inadequately relieved physical and psychological symptoms. The All Wales Clinical Trials Unit is also directed from centre, which participates in clinical research related to the quality of life of cancer patients, including end stage disease. The education programme and clinical process audits fully integrate oncology and palliative care services and have demonstrated rapidly improved symptoms in patients admitted in the palliative or terminal stages of malignancy.
Additional Contact Person: Prof. Ilora Finlay , Ilora.email@example.com